Clinical

Dataset Information

0

Early tumor shrinkage of Cetuximab and mFOLFOX6 in RAS-wild type unresectable metastatic colorectal cancer.


ABSTRACT: Interventions: Weekly Cetuximab+mFOLFOX6 Cetuximab 400mg/m2/ initial 250mg/m2/ qw Oxaliplatin 85mg/m2/ qw l-LV 200mg/m2/ qw 5FU-bols 400mg/m2/ qw 5FU-infusional 2,400mg/m2/ qw OR Biweekly Cetuximab+mFOLFOX6 Cetuximab 500mg/m2/ q2w Oxaliplatin 85mg/m2/ q2w l-LV 200mg/m2/ q2w 5FU-bols 400mg/m2/ q2w 5FU-infusional 2,400mg/m2/ q2w Primary outcome(s): ETS(Early Tumor Shrinkage) rate Study Design: Single arm Non-randomized

DISEASE(S): Ras-wild Type Colorectal Cancer

PROVIDER: 2630670 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2633492 | ecrin-mdr-crc
| 2623948 | ecrin-mdr-crc
| 2622536 | ecrin-mdr-crc
| 2620254 | ecrin-mdr-crc
| 2620327 | ecrin-mdr-crc
| 2623785 | ecrin-mdr-crc
| 2620377 | ecrin-mdr-crc
| 2621954 | ecrin-mdr-crc
| 2621834 | ecrin-mdr-crc
| 2622610 | ecrin-mdr-crc